IL1B and cardiovascular disorder: The CANTOS study showed that canakinumab, a human monoclonal anti-human IL-1β antibody, could reduce the risk of major cardiovascular disease events in patients with a history of myocardial infarction without any effect on lipid levels, which demonstrated that anti-inflammatory therapy inhibiting the IL-1 pathway might indeed be beneficial for patients with coronary heart disease (50).